Posicor's removal from the market

July 1998

Posicor's removal from the market, less than a year after itwas approved, shows how hard it is to predict drug interactions.

Posicor inhibits cytochrome P450 enzymes that are important formetabolizing many other drugs. This can allow other drugs to buildup to toxic levels...or prevent the formation of active metabolites.

Posicor (mibefradil) can interact with more than 25 drugsincluding other calcium blockers...beta-blockers...erythromycin...lovastatin...digoxin...and quinidine.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

grapefruit juices can increase levels of Mevacor (lovastatin)
Cardiology "Hypertension Optimal Treatment" study
Cardiology Posicor's removal from the market
Vitamin E seems to reduce the risk of prostate cancer
7-keto DHEA
Women's Health Prometrium, the first commercially available form of ORAL micronized progesterone
Hepatitis C Hepatitis C is a growing problem
Gastroenterology patients can reduce embarrassing flatulence odor by using Pepto-Bismol (bismuth subsalicylate)
Diabetes the NIH is no longer using Rezulin (troglitazone) in their large Diabetes Prevention Study
Diabetes replacing SureStep meters made before August '97
Neurology & Pain Duract (bromfenac) was on the market less than a year
Transdermal Patches whether it's okay to cut patches in half
best way to prevent and treat mosquito bites
Pediatrics shorter course of antibiotics for uncomplicated cases of acute otitis media (AOM)

Posicor's removal from the market

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents